Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...
Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback